$MRAI News

MARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Marpai Q1 EPS $(0.13) Up From $(0.21) YoY, Sales $4.444M Down From $5.418M YoY

Marpai, Inc. Announces Significant New Business Wins across TPA and MarpaiRx; Solidifies Forecast for Profitability

Marpai, Inc. Secures Major Strategic Marketing Collaboration to Continue Acceleration of MarpaiRx Growth Nationwide

Marpai Q4 EPS $(0.26) Down From $(0.08) YoY, Sales $3.988M Down From $6.591M YoY

Marpai Secures Access to Network Creating Major Growth Catalyst for MarpaiRx Representing Up to 1.5 million Covered Lives

Marpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform Expansion

MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

MARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSION

Marpai, Inc. (MRAI) Q3 2025 Earnings Call Transcript

MARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Marpai Q3 EPS $(0.20) Up From $(0.30) YoY, Sales $4.037M Down From $7.008M YoY

MARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS

MARPAI RECOGNIZED AS 2025 TOP THIRD PARTY ADMINISTRATOR

MARPAI, INC. RECEIVES ADDITIONAL $200,000 INVESTMENT FROM DAMIEN LAMENDOLA'S HILLCOUR INVESTMENT FUND

Marpai, Inc. (MRAI) Q2 2025 Earnings Call Transcript

MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Marpai Q2 EPS $(0.28) Up From $(1.23) YoY, Sales $4.656M Down From $7.189M YoY

MARPAI TO HOST WEBCAST ON AUGUST 14, 2025 TO DISCUSS SECOND QUARTER 2025 FINANCIAL RESULTS

MARPAIRX REVOLUTIONIZES PHARMACY BENEFITS WITH UNPRECEDENTED TRANSPARENCY AND SAVINGS